Nyrada Inc. (NYR.AX)
AUD 0.1
(-2.0%)
AUD 0.1
(-2.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 855.63 Thousand AUD | -5.59% |
| 2023 | 906.28 Thousand AUD | 75.81% |
| 2022 | 515.47 Thousand AUD | -22.53% |
| 2021 | 665.38 Thousand AUD | -10.16% |
| 2020 | 740.66 Thousand AUD | -87.85% |
| 2019 | 6.09 Million AUD | 34.52% |
| 2018 | 4.53 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 855.63 Thousand AUD | -5.59% |
| 2024 Q4 | 855.63 Thousand AUD | 0.0% |
| 2024 Q2 | 484.5 Thousand AUD | 0.0% |
| 2023 Q2 | 1.21 Million AUD | 0.0% |
| 2023 FY | 906.28 Thousand AUD | 75.81% |
| 2023 Q4 | 906.28 Thousand AUD | 0.0% |
| 2022 Q4 | 515.47 Thousand AUD | 0.0% |
| 2022 Q2 | 495.43 Thousand AUD | 0.0% |
| 2022 FY | 515.47 Thousand AUD | -22.53% |
| 2021 FY | 665.38 Thousand AUD | -10.16% |
| 2021 Q4 | 665.38 Thousand AUD | 0.0% |
| 2021 Q2 | 744.2 Thousand AUD | 0.0% |
| 2020 Q4 | 740.66 Thousand AUD | 0.0% |
| 2020 FY | 740.66 Thousand AUD | -87.85% |
| 2020 Q2 | 7.54 Million AUD | 0.0% |
| 2019 FY | 6.09 Million AUD | 34.52% |
| 2019 Q4 | 6.09 Million AUD | 0.0% |
| 2019 Q1 | - AUD | 0.0% |
| 2018 FY | 4.53 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 79.768% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -178.845% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 90.855% |
| Biome Australia Limited | 5.37 Million AUD | 84.076% |
| Patrys Limited | 691.36 Thousand AUD | -23.76% |
| Orthocell Limited | 22.08 Million AUD | 96.125% |
| Imugene Limited | 33.14 Million AUD | 97.418% |
| Noxopharm Limited | 1.28 Million AUD | 33.601% |
| PYC Therapeutics Limited | 10.18 Million AUD | 91.598% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 93.317% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 63.207% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 47.376% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 26.935% |
| CSL Limited | 27.88 Billion AUD | 99.997% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 58.396% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -132.228% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 96.956% |
| Starpharma Holdings Limited | 8.69 Million AUD | 90.163% |
| Nanollose Limited | 465.64 Thousand AUD | -83.753% |
| Memphasys Limited | 5.59 Million AUD | 84.7% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -98.233% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -898.603% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 75.031% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 77.074% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 18.17% |
| Race Oncology Limited | 1.91 Million AUD | 55.353% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.657% |
| Dimerix Limited | 13.89 Million AUD | 93.841% |
| PharmAust Limited | 896.6 Thousand AUD | 4.57% |
| Immutep Limited | 10.97 Million AUD | 92.207% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 89.73% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 84.23% |
| BTC Health Limited | 203.94 Thousand AUD | -319.535% |
| Acrux Limited | 5.68 Million AUD | 84.955% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 97.999% |
| Biotron Limited | 737.5 Thousand AUD | -16.017% |
| Tissue Repair Ltd | 1.35 Million AUD | 36.662% |
| AdAlta Limited | 3.54 Million AUD | 75.847% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 98.085% |
| Hexima Limited | 248.67 Thousand AUD | -244.084% |
| AnteoTech Limited | 4.07 Million AUD | 79.004% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 76.129% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 94.616% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 9.124% |
| Actinogen Medical Limited | 1.61 Million AUD | 47.032% |
| Immuron Limited | 2.84 Million AUD | 69.878% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 64.741% |